A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI13K Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Start Date
February 12, 2018
End Date
October 21, 2020
Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Start Date
February 12, 2018
End Date
October 21, 2020